Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

Completed · Phase 2 · Has a placebo group

Conditions studied: Parkinson's Disease, Cognitive Impairment

In brief

The purpose of this study is to determine the safety and effectiveness of a drug called atomoxetine for the treatment of cognitive impairment for Parkinson 's disease. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD.

Key facts

Study ID
NCT01738191
Run by
Medical University of South Carolina
People needed
30
Starts
2012-11-01
Expected to finish
2014-08-01
Last updated by the study team
2018-08-23

Who can join

Age: 35 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.